Get the latest industry news first when you subscribe to our daily newsletter.
Policy, Artificial Intelligence, Health Tech
By Elise Reuter
The Centers for Medicare and Medicaid Services (CMS) will cover an autonomous screening tool and allow it to count toward quality measures. As part of its 2022 Medicare Physician Fee Schedule, CMS set a national payment amount for using AI to detect diabetic retinopathy.
It also included these screenings as a quality measure, saying that eye exams must be performed by an ophthalmologist or optometrist, or that retinal images must be read by a system that provides an AI interpretation.
Diabetic retinopathy is a condition where high blood sugar levels can cause damage to the blood vessels in the retina. It can go undetected until its later stages, when it starts to affect patients’ vision.
Because of this, annual eye exams are recommended for patients with Type 1 or Type 2 diabetes. But in practice, that doesn’t always happen. One study of hospitalized patients with diabetes found that less than half of them had an eye exam in the last year.
Some commenters contended that quality measures should only apply when the software system is FDA approved, or that equally considering a comprehensive eye exam and an AI-based screening to denote care quality is not appropriate.
In response, CMS wrote, “We believe that allowing AI will increase the accessibility and therefore occurrence of yearly eye exams, leading to quality outcomes in this patient population.”
The decision was also cheered by two companies that make AI-based screening systems for diabetic retinopathy, Digital Diagnostics and Eyenuk.
“These final regulations will allow eye exams to be administered at patients’ point-of-care where they receive diabetes management eliminating many barriers to care and increasing access,” Digital Diagnostics Founder and Chairman Dr. Michael D Abramoff said in a news release.
Digital Diagnostics (formerly known as IDx) got a de novo clearance from the Food and Drug Administration in 2018 for its software to automatically detect diabetic retinopathy. Images taken with a retinal camera are uploaded and processed by its algorithm, which screens for moderate- to severe- retinopathy. It would either indicate to a physician that diabetic retinopathy is present or that the screening was negative.
Notably, the device was cleared to make screening decisions on its own, meaning it could be used by primary care physicians and other providers that don’t specialize in eye care.
While physicians in a Nature editorial touted the clearance as an important milestone, they also raised up a few shortcomings with these automated tools. For instance, they wrote that the study that served as the basis for the device’s FDA decision was still relatively small in terms of diagnostic accuracy, and that because it is only designed to detect diabetic retinopathy, it might miss other conditions that would be detected in an eye exam, such as glaucoma or macular degeneration.
Eyenuk, for its part, got 510(k) clearance for its system last year.
Photo credit: memorisz, Getty Images
For researchers who aren’t affiliated with an academic library, finding scientific papers can be time-consuming and expensive—and organizing and sharing them with co-workers can be even harder. A new tool by DeepDyve looks to help researchers address this gap.
DeepDyve Digital Library Team
It’s clear that life science companies need to transform their approach to be much more collaborative in the way they work with healthcare professionals.
Microsoft and MedCity News
AI, CMS, diabetic retinopathy, Medicare
The report, Resilience in volatility: Modernizing the supply chain, highlights three areas that Fortune 500 and mid-size companies need to address to implement technology such as machine learning, cloud computing and risk management tools to improve production and delivery.
MedCity News and Microsoft
MedCity INVEST, held March 28-30, 2022 at the Ritz-Carlton Chicago, is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with the most promising healthcare startups. Reserve your spot now.>>
GOT NEWS? SEND US A TIP
Get the latest industry news first when you subscribe to our newsletter.
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such as the rise of neuro-immunology and the industry’s embrace of digital health tools to support drug development in a recent interview.
Privacy Center | Do not sell my information